CO2017002714A2 - Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo - Google Patents

Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo

Info

Publication number
CO2017002714A2
CO2017002714A2 CONC2017/0002714A CO2017002714A CO2017002714A2 CO 2017002714 A2 CO2017002714 A2 CO 2017002714A2 CO 2017002714 A CO2017002714 A CO 2017002714A CO 2017002714 A2 CO2017002714 A2 CO 2017002714A2
Authority
CO
Colombia
Prior art keywords
acid
naphthyridin
methoxyethoxy
pyrrolidin
tetrahydro
Prior art date
Application number
CONC2017/0002714A
Other languages
English (en)
Inventor
Niall Andrew Anderson
John Martin Pritchard
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO2017002714A2 publication Critical patent/CO2017002714A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I): que es ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2- metoxietoxi)fenil)butanoico, o una sal del mismo.
CONC2017/0002714A 2014-09-26 2017-03-22 Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo CO2017002714A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
PCT/EP2015/071776 WO2016046225A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
CO2017002714A2 true CO2017002714A2 (es) 2017-06-30

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002714A CO2017002714A2 (es) 2014-09-26 2017-03-22 Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo

Country Status (36)

Country Link
US (3) US9956209B2 (es)
EP (2) EP3197892B1 (es)
JP (1) JP6611799B2 (es)
KR (1) KR101998000B1 (es)
CN (1) CN107074848B (es)
AR (1) AR101994A1 (es)
AU (1) AU2015320858B2 (es)
BR (1) BR112017006251A2 (es)
CA (1) CA2962315A1 (es)
CL (1) CL2017000705A1 (es)
CO (1) CO2017002714A2 (es)
CR (1) CR20170112A (es)
CY (1) CY1121071T1 (es)
DK (1) DK3197892T3 (es)
DO (1) DOP2017000081A (es)
EA (1) EA031481B1 (es)
ES (1) ES2690748T3 (es)
GB (1) GB201417002D0 (es)
HR (1) HRP20181796T1 (es)
HU (1) HUE041827T2 (es)
IL (1) IL250592A0 (es)
JO (1) JO3413B1 (es)
LT (1) LT3197892T (es)
MA (1) MA40580B1 (es)
MX (1) MX2017003948A (es)
PE (1) PE20170502A1 (es)
PH (1) PH12017500361A1 (es)
PL (1) PL3197892T3 (es)
PT (1) PT3197892T (es)
RS (1) RS58000B1 (es)
SG (1) SG11201701183YA (es)
SI (1) SI3197892T1 (es)
TW (1) TW201629056A (es)
UA (1) UA119181C2 (es)
UY (1) UY36314A (es)
WO (1) WO2016046225A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US10745384B2 (en) 2016-11-08 2020-08-18 Bristol-Myers Squibb Company Indazole derivatives as αv integrin antagonists
EA038164B1 (ru) 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
KR102510858B1 (ko) 2016-11-08 2023-03-15 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
EA201991124A1 (ru) * 2016-11-08 2019-10-31 ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND METHOD FOR USE
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CA3054604A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
EP3596105B1 (en) * 2017-03-17 2023-12-27 Technische Universität München Ligands for integrin .alpha.v.beta.8, synthesis and uses thereof
AU2018365793A1 (en) 2017-11-07 2020-06-18 Bristol-Myers Squibb Company Pyrrolopyrazine derivatives as alpha V integrin inhibitors
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
EP3843727A4 (en) * 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS
UY38352A (es) * 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
TW202035400A (zh) * 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 抑制αvβ6整合素
EP3843728A4 (en) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
IL136495A0 (en) 1997-12-17 2001-06-14 Merck & Co Inc Integrin receptor antagonists
ES2288861T3 (es) 1999-06-02 2008-02-01 MERCK & CO., INC. Antagonistas de los receptores de las integrinas alfa v.
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
WO2001024797A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
JP2003513974A (ja) 1999-11-08 2003-04-15 メルク エンド カムパニー インコーポレーテッド イミダゾリジノン系αｖ−インテグリン拮抗薬の製造方法および製造用中間体
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
AU2001277935B2 (en) 2000-07-26 2005-08-04 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
EP1349548A4 (en) 2001-01-03 2004-06-02 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING PERIODONTOSIS
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
WO2003100033A2 (en) 2002-03-13 2003-12-04 Biogen Idec Ma Inc. ANTI-αvβ6 ANTIBODIES
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
CA2507699A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
AU2008231385B2 (en) 2007-03-23 2012-02-02 Amgen Inc. Delta3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase ( PI3K) inhibitors
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
CL2017000705A1 (es) 2017-11-03
CY1121071T1 (el) 2019-12-11
KR20170055489A (ko) 2017-05-19
EA201790715A1 (ru) 2017-07-31
US10342783B2 (en) 2019-07-09
US20180271845A1 (en) 2018-09-27
PE20170502A1 (es) 2017-04-27
CR20170112A (es) 2017-05-26
PT3197892T (pt) 2018-12-12
MA40580A (fr) 2017-08-02
UA119181C2 (uk) 2019-05-10
JP6611799B2 (ja) 2019-11-27
BR112017006251A2 (pt) 2017-12-12
TW201629056A (zh) 2016-08-16
AR101994A1 (es) 2017-01-25
JP2017528507A (ja) 2017-09-28
EP3197892B1 (en) 2018-09-05
US20170290817A1 (en) 2017-10-12
EP3197892A1 (en) 2017-08-02
CN107074848B (zh) 2019-11-01
HRP20181796T1 (hr) 2018-12-28
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
RS58000B1 (sr) 2019-01-31
JO3413B1 (ar) 2019-10-20
AU2015320858B2 (en) 2018-10-18
WO2016046225A1 (en) 2016-03-31
DK3197892T3 (en) 2018-11-26
SG11201701183YA (en) 2017-04-27
DOP2017000081A (es) 2017-04-30
KR101998000B1 (ko) 2019-07-08
ES2690748T3 (es) 2018-11-22
PH12017500361B1 (en) 2017-07-17
PH12017500361A1 (en) 2017-07-17
US9956209B2 (en) 2018-05-01
MX2017003948A (es) 2017-06-26
CA2962315A1 (en) 2016-03-31
EP3428167A1 (en) 2019-01-16
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
EA031481B1 (ru) 2019-01-31
MA40580B1 (fr) 2018-09-28
UY36314A (es) 2016-04-29
US20190275016A1 (en) 2019-09-12
HUE041827T2 (hu) 2019-05-28
PL3197892T3 (pl) 2019-05-31
CN107074848A (zh) 2017-08-18
AU2015320858A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
EA201790271A1 (ru) Ингибиторы гликозидазы
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201791304A1 (ru) Производные изохинолина для лечения вич
PE20150617A1 (es) Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
RS54730B1 (sr) Inhibitori beta sekretaze
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
CL2018001067A1 (es) Compuesto piranodipiridínico.
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
AR107163A1 (es) Inhibidores de quinasa
PH12017500492A1 (en) Crystalline bace inhibitors
PE20171259A1 (es) Compuestos
EA201791596A1 (ru) Пиразоловые соединения